Lyra Therapeutics Inc Ordinary Shares LYRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LYRA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $4.72
- Day Range
- $4.70–5.02
- 52-Week Range
- $2.36–6.79
- Bid/Ask
- $4.46 / $7.00
- Market Cap
- $282.58 Mil
- Volume/Avg
- 302,755 / 359,990
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 151.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company’s operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 88
- Website
- https://lyratherapeutics.com
Comparables
Valuation
|
Metric
|
LYRA
|
CBAY
|
DSGN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.03 | 12.65 | 0.76 |
Price/Sales | 151.21 | 111.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
LYRA
CBAY
DSGN
Financial Strength
|
Metric
|
LYRA
|
CBAY
|
DSGN
|
|---|---|---|---|
Quick Ratio | 5.24 | 10.70 | 29.44 |
Current Ratio | 5.35 | 10.96 | 29.58 |
Interest Coverage | — | −5.27 | — |
Quick Ratio
LYRA
CBAY
DSGN
Profitability
|
Metric
|
LYRA
|
CBAY
|
DSGN
|
|---|---|---|---|
Return on Assets (Normalized) | −47.89% | −30.06% | −17.16% |
Return on Equity (Normalized) | −67.73% | −51.97% | −17.93% |
Return on Invested Capital (Normalized) | −65.54% | −30.87% | −17.73% |
Return on Assets
LYRA
CBAY
DSGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vjsqyhxdq | Qlks | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bvvmgsmm | Gsxvjb | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kbbxhcwm | Pqvcyy | $98.3 Bil | |
MRNA
| Moderna Inc | Fpndyqznm | Hnfl | $42.7 Bil | |
ARGX
| argenx SE ADR | Blkrsyh | Khrn | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Yzcgydx | Hqn | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vpmsndm | Ylsnzc | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vvtkxrmhf | Fszmbql | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ynpblkfy | Jvdmldg | $12.7 Bil | |
INCY
| Incyte Corp | Pvwtysng | Rxngfyh | $11.8 Bil |